Fviii muteins for treatment of von willebrand disease
作者： Xin Zhang , Tongyao Liu , John E. Murphy , Glenn Pierce , Haiyan Jiang
DOI:
关键词:
摘要: This invention relates to treatment of von Willebrand Disease by administration Factor VIII muteins that are covalently bound, at a predefined site is not an N-terminal amine, one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties in subjects lacking Factor.
google.com.mx 参考文章(9)
Alan J. Johnson, Anne J. Fulton, Modified factor VIII ,(1989)
Bernard Dazey, Gerard Vezon, Mohamed Hamsany, Process for manufacturing von Willebrand factor ,(1991)
Paul D. Bishop, Method for treating von willebrand's disease ,(2002)
Anna-Lisa Smeds, Helena Sandberg, Eva Akerblom, Johanna Dalborg, Conjugates of a polypeptide and a biocompatible polymer ,(1996)
Pier Mannuccio Mannucci, How I treat patients with von Willebrand disease Blood. ,vol. 97, pp. 1915- 1919 ,(2001) , 10.1182/BLOOD.V97.7.1915
Terrence W. Hallahan, Carl W. Gilbert, Factor IX- polymeric conjugates ,(1994)
Hendri Tjandra, Clark Q. Pan, John E. Murphy, Baisong Mei, Liang Tang, Jonathan S. Strauss, Jianmin Chen, Deqian Wang, Thomas Barnett, Site-directed modification of FVIII ,(2005)
Ping Zhang, Michael D. Bentley, Mary J. Bossard, Polymer-factor VIII moiety conjugates ,(2004)
Peter J. Lenting, Jan A. van Mourik, Koen Mertens, The life cycle of coagulation factor VIII in view of its structure and function. Blood. ,vol. 92, pp. 3983- 3996 ,(1998) , 10.1182/BLOOD.V92.11.3983